menu
Orano Med wins the "Innovation of the Year" award at the Grand Dîner de L'Usine Nouvelle
Orano Med, a subsidiary of the Orano group specialized in nuclear medicine, won the "Innovation of the Year" ("l’Innovation de l’année") award at the Grand Dîner de L'Usine Nouvelle for leaders of French industry held in Paris on Tuesday October 7.
Orano Med is a biotech company which is developing a new generation of targeted therapies against cancer using the unique properties of lead-212, a radioactive element with a very potent therapeutic payload. This “Targeted Alpha Therapy” approach opens new avenues for patients with cancer and limited options for treatment.
Targeted Alpha Therapy relies on a simple concept: combining the ability of biological molecules to target cancer cells with the cell-killing capabilities of alpha-emitting radioisotopes, while limiting the impact on surrounding healthy cells.
Orano Med's ambition is to develop and commercialize these innovative therapies. To achieve this, its teams have to master every step of a complex process: from preclinical research and clinical development through to the production and distribution of Targeted Alpha Therapies worldwide.
Guillaume Dureau, Senior Executive Vice President of the Projects Business Unit – Director of Innovation, R&D and New Activities said: "This award marks the culmination of 15 years of continuous work on innovation and collective commitment. I am proud to contribute to this unique venture! Orano Med is born of a strong ambition of the group: to recover nuclear materials for use in the health sector. Since then, we have taken some major steps forward – with the development of a robust pipeline lead-212-based drugs, the signature of an out-licensing agreement for AlphaMedixTM, the entry of Sanofi into our capital, and the development of our industrial platform to enable us to meet the expectations of patients worldwide."
Arnaud Lesegretain, President and CEO of Orano Med added "It is an honor to receive this Innovation of the Year award, on behalf of the whole team at Orano Med and in the company of its founder Patrick Bourdet. This award is recognition of the unfailing commitment of the Orano group and our employees since Orano Med's creation in 2009. Since then, we have been bold in our commitment to the path of progress in medical research and the fight against cancer. Orano Med is now imposing itself as a pioneer and leader in the sector worldwide, developing a new generation of targeted therapies for patients not responding to existing treatments."
Orano Med is a biotech company which is developing a new generation of targeted therapies against cancer using the unique properties of lead-212, a radioactive element with a very potent therapeutic payload. This “Targeted Alpha Therapy” approach opens new avenues for patients with cancer and limited options for treatment.
Targeted Alpha Therapy relies on a simple concept: combining the ability of biological molecules to target cancer cells with the cell-killing capabilities of alpha-emitting radioisotopes, while limiting the impact on surrounding healthy cells.
Orano Med's ambition is to develop and commercialize these innovative therapies. To achieve this, its teams have to master every step of a complex process: from preclinical research and clinical development through to the production and distribution of Targeted Alpha Therapies worldwide.
Guillaume Dureau, Senior Executive Vice President of the Projects Business Unit – Director of Innovation, R&D and New Activities said: "This award marks the culmination of 15 years of continuous work on innovation and collective commitment. I am proud to contribute to this unique venture! Orano Med is born of a strong ambition of the group: to recover nuclear materials for use in the health sector. Since then, we have taken some major steps forward – with the development of a robust pipeline lead-212-based drugs, the signature of an out-licensing agreement for AlphaMedixTM, the entry of Sanofi into our capital, and the development of our industrial platform to enable us to meet the expectations of patients worldwide."
Arnaud Lesegretain, President and CEO of Orano Med added "It is an honor to receive this Innovation of the Year award, on behalf of the whole team at Orano Med and in the company of its founder Patrick Bourdet. This award is recognition of the unfailing commitment of the Orano group and our employees since Orano Med's creation in 2009. Since then, we have been bold in our commitment to the path of progress in medical research and the fight against cancer. Orano Med is now imposing itself as a pioneer and leader in the sector worldwide, developing a new generation of targeted therapies for patients not responding to existing treatments."
About Orano Med
Orano Med, a subsidiary of the Orano Group, is a clinical-stage biotechnology company which develops a new generation of targeted therapies against cancer using the unique properties of lead-212 (212Pb), an alpha-emitting radioisotope and one of the more potent therapeutic payloads against cancer cells known as Targeted Alpha-Emitter Therapy (TAT). AlphaMedix, its most advanced asset in clinical development for GEP-NETs tumors, received Breakthrough Designation from the FDA in 2024. The company is advancing several potential treatments using 212Pb combined with various targeting agents through clinical and preclinical studies. Orano Med has 212Pb manufacturing facilities, laboratories, and R&D centers in France and in the US. It is expanding its GMP-manufacturing capacities for 212Pb radiolabeled pharmaceuticals in North America and Europe and building a unique, independent, and fully integrated industrial platform to serve the needs of patients globally.
About Orano
As a recognized international leading operator in the field of nuclear materials, Orano delivers solutions to address present and future global energy and health challenges. Its expertise and mastery of cutting-edge technologies enable Orano to offer its customers high value-added products and services throughout the entire fuel cycle. Every day, the Orano group’s 17,500 employees draw on their skills, unwavering dedication to safety and constant quest for innovation, with the commitment to develop know-how in the transformation and control of nuclear materials, for the climate and for a healthy and resource-efficient world, now and tomorrow.
Orano, giving nuclear energy its full value.
Head Office
125 avenue de Paris
92320 Châtillon
Tel. : +33 (0)1 34 96 00 00
Fax : +33 (0)1 34 96 00 01
Press Contacts
Sophie Letournel
Head of Strategy, Governance and Communications
sophie.letournel@orano.group
Tel. : +33 6 38 44 34 11
Press Office Orano
Tel.: +33 (0)1 34 96 12 15
press@orano.group